Noninvasive bioelectric therapy for dry AMD enters pivotal trial

Dry age-related macular degeneration affects millions globally, characterized by the accumulation of drusen and geographic atrophy in the macula. This progressive neurodegenerative condition of the retina leads to central vision impairment, severely impacting quality of life. Current management primarily focuses on lifestyle modifications and nutritional supplements, particularly the AREDS formulation, which can slow progression in some intermediate cases but does not restore lost vision or treat advanced disease.

This study, which will determine if the therapy can gain regulatory approval, will evaluate the device's ability to preserve or improve visual function and reduce the progression of geographic atrophy. The trial design typically involves a placebo or sham control group to rigorously assess the device's efficacy against the natural history of the disease. Endpoints commonly include changes in best-corrected visual acuity (BCVA), lesion size, and patient-reported outcomes related to vision quality.

The Clinical Rationale

The rationale for bioelectric stimulation in dry AMD stems from preclinical and early clinical observations suggesting that electrical fields can influence retinal cell health and function. These effects may include enhancing mitochondrial activity, reducing oxidative stress, and promoting the survival of photoreceptors and retinal pigment epithelial cells. Such mechanisms are critical, given the pathophysiology of dry AMD, which involves chronic inflammation, oxidative damage, and cellular dysfunction.

But the precise mechanisms by which bioelectric therapy might exert its effects in the complex environment of the degenerating retina are still under investigation. Early studies have explored various parameters of electrical stimulation, including frequency, intensity, and duration, to optimize potential therapeutic benefits. The noninvasive nature of this device offers a distinct advantage over intravitreal injections or surgical interventions, potentially improving patient adherence and reducing treatment burden.

The success of the study, which will determine if the therapy can gain regulatory approval, hinges on demonstrating a clinically meaningful benefit that outweighs any potential risks. For a condition like dry AMD, even a modest slowing of disease progression would be considered valuable. Clinicians often discuss the benefits of anti-VEGF therapies for wet AMD, but the conversation for dry AMD patients remains largely about managing expectations and supporting low vision. For a broader overview of ophthalmic conditions, the Oxford Handbook of Ophthalmology provides a concise reference.

What the Trial Aims to Show

The study, which will determine if the therapy can gain regulatory approval, is designed to provide definitive evidence on the efficacy and safety of this bioelectric therapy. It will enroll a large cohort of patients with intermediate to advanced dry AMD, including those with geographic atrophy. The primary outcome measures will likely focus on changes in visual acuity and the rate of progression of geographic atrophy, as measured by imaging techniques such as optical coherence tomography (OCT).

Secondary endpoints will include assessments of contrast sensitivity, reading speed, and quality of life questionnaires. Safety monitoring will be rigorous, looking for any adverse events related to device use. The long-term durability of any observed effects will also be a critical consideration, as dry AMD is a chronic, progressive condition. This trial builds on earlier exploratory work, much like how stereotactic radiotherapy has been investigated for nAMD to reduce injection burden.

The open-label design of some earlier studies is an obvious caveat, as patient and investigator expectations can influence subjective outcomes. A well-designed, sham-controlled study that will determine if the therapy can gain regulatory approval is essential to provide unbiased data. The trial will need to demonstrate not just statistical significance, but also clinical relevance, meaning the observed benefits must translate into tangible improvements in patients' daily lives.

The development of novel therapies for dry AMD is a high-priority area, given the aging global population and the increasing prevalence of the disease. While this bioelectric therapy is still investigational, its progression to a study that will determine if the therapy can gain regulatory approval signals a potential new avenue for treatment. The field has seen other non-pharmacological interventions, such as semaglutide's potential impact on AMD risk, but direct treatment for dry AMD remains elusive.